Abstract: Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the FIG. 5 treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

Abstract: Advancements in solid tumor (e.g., renal cell carcinoma) treatments and imaging are described. The advancements are based on nanoformulations that: (i) overcome deliverability issues associated with anti-cancer compounds; (ii) have increased targeted delivery to tumors, and hypoxic cores of tumors due to the presence of targeting ligands; (iii) have increased delivery to the hypoxic cores of tumors due to engineered shapes; (iv) provide synergistic treatment combinations; and/or (v) overcome cancer cell resistance to therapeutic treatments.

Abstract: A composition for targeted delivery of a therapeutic agent is provided herein, the composition including poly(styrene-co-maleic acid) (SMA) covalently conjugated to hyaluronic acid (HA). The HA-SMA composition optionally forms a micelle for targeted delivery of a therapeutic agent. Also provided herein is a method of treating a condition by administering a therapeutically-effective amount of a composition including HA-SMA conjugate and a non-covalently associated therapeutic agent, optionally further including curcumin difluorinated (CDF) or other therapeutic agent.

Abstract: Libraries of nanoparticles comprising therapeutic agents and/or imaging agents are disclosed, as well as methods of making, customizing, and using such libraries of nanoparticles.

Abstract: Biodegradable pH altering polymers are disclosed. In accordance with certain aspects, the biodegradable pH altering polymers may be used to alter the pH of a microenvironment. In accordance with other aspects, the biodegradable pH altering polymers are utilized for targeted drug and gene delivery and their spontaneous release in intracellular sites of interest.

Abstract: Libraries of nanoparticles comprising therapeutic agents and/or imaging agents are disclosed, as well as methods of making, customizing, and using such libraries of nanoparticles.